Actigall
In brief
- In our pharmacy, you can buy actigall without a prescription, with delivery in 9–21 days throughout Australia. Discreet and anonymous packaging.
- Actigall (ursodeoxycholic acid) is used to dissolve non‑calcified cholesterol gallstones, to help prevent gallstones during rapid weight loss and as chronic therapy for primary biliary cholangitis; it is a hydrophilic bile acid that reduces cholesterol saturation in bile, promotes bile flow and has cytoprotective and immunomodulatory effects.
- The usual dose is 8–10 mg/kg/day for gallstone dissolution (commonly 300 mg twice daily), 300 mg twice daily for prevention during rapid weight loss, and 13–15 mg/kg/day divided for primary biliary cholangitis.
- Actigall is given orally as capsules or tablets — commonly 300 mg capsules and 250 mg or 500 mg tablets.
- Onset: biochemical changes in bile can be seen within days to weeks and some symptomatic improvement within weeks, but actual gallstone dissolution typically takes months (commonly 6–24 months).
- Duration of action: plasma half‑life is short (around 3–6 hours), but clinical benefit requires continuous long‑term use — months for gallstones and often long‑term or lifelong treatment for PBC.
- Alcohol warning: avoid or minimise alcohol while taking actigall, especially if you have underlying liver disease — alcohol can worsen liver function and should be discussed with a clinician.
- The most common side effect is diarrhoea; other frequent effects include nausea, mild abdominal pain and rash.
- Would you like to try actigall without a prescription?
Basic Actigall Information
- INN (International Nonproprietary Name): Ursodeoxycholic Acid (commonly referred to as ursodiol)
- Brand Names Available In Australia: Not specified
- ATC Code: A05AA02 – Ursodeoxycholic acid
- Forms & Dosages: Capsules 300 mg; tablets 250 mg and 500 mg
- Manufacturers In Australia: Not specified
- Registration Status In Australia: Not specified
- OTC / Rx Classification: Prescription-only (Rx)
Critical Warnings & Restrictions
High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)
People often ask whether actigall or ursodeoxycholic acid is safe if they have other illnesses.
Ursodeoxycholic acid (UDCA, also called ursodiol) is generally well tolerated but needs caution in higher‑risk Australians.
Absolute contraindications include complete biliary or gallbladder obstruction and known hypersensitivity to the medicine or its ingredients.
Avoid using UDCA in decompensated cirrhosis and in acute cholangitis unless managed by a specialist.
Pregnancy and breastfeeding require a specialist risk–benefit discussion before starting therapy.
Elderly people need a close review of concurrent medicines, especially where polypharmacy is present.
Baseline liver function tests (LFTs) and ongoing monitoring are recommended while on UDCA.
Therapy should be supervised by the prescriber or a hepatologist for patients with chronic liver disease.
The product information lists the absolute contraindications and stresses caution in advanced liver disease.
Use this immediate actions checklist if a problem is suspected:
- Stop the medicine if there are signs of an allergic reaction such as rash, swelling or breathing difficulty.
- Seek urgent medical care for new or worsening jaundice, severe abdominal pain or fever suggesting cholangitis.
- Contact your prescriber promptly for abnormal LFTs or new concerning symptoms.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
UDCA is not a sedative, but common side effects such as diarrhoea, dizziness or nausea can impair fitness to drive.
Australian road safety laws require you not to drive if a medicine affects your ability to drive safely.
If you work in a safety‑critical role your employer may require medical clearance or workplace adjustments while you start or increase UDCA.
Q&A — “Can I Drive After Taking It In Australia?”
Usually yes — UDCA does not commonly cause drowsiness.
If you experience diarrhoea, dizziness or impaired concentration, do not drive and contact your prescriber or pharmacist.
Check the product information and local road‑safety guidance if you are unsure about fitness to drive.
Usage Basics
INN, Brand Names Available In Australia
The international non‑proprietary name is ursodeoxycholic acid, commonly shortened to UDCA or ursodiol.
Globally marketed brand names include Actigall, Urso, Urso 250, Urso Forte and Reltone, though Australian trade names should be checked via the TGA ARTG.
Common dosage forms internationally are capsules 300 mg and tablets 250 mg and 500 mg.
Pharmacies will list the registered brand or approved generic on the dispensing label, and availability may vary between suppliers.
Legal Classification (TGA‑Approved, PBS‑Listed)
Ursodeoxycholic acid is classified as prescription‑only under major regulators and is prescription‑only in Australia.
PBS subsidy and authority requirements depend on the indication, for example chronic cholestatic disease versus short‑term gallstone dissolution.
Clinicians and pharmacists should confirm ARTG entries and current PBS criteria before prescribing or claiming subsidy.
For patient counselling, compare brand, strength and PBS status at the time of dispensing to avoid unexpected out‑of‑pocket costs.
Dosing Guide
Standard Regimens (PBS Reference Dosing)
Dosing with ursodeoxycholic acid depends on the indication and the patient’s weight.
For dissolving non‑calcified cholesterol gallstones the recommended range is 8–10 mg/kg/day, which often translates practically to 300 mg twice daily for many adults.
Prevention of gallstones during rapid weight loss—such as in bariatric pathways—commonly uses 300 mg twice daily.
For primary biliary cholangitis (PBC) the usual maintenance dose is approximately 13–15 mg/kg/day divided into two or three doses.
Treatment duration varies by indication: gallstone therapy typically lasts 6–24 months with imaging to confirm dissolution.
PBC treatment is usually long‑term with ongoing monitoring of clinical response and LFTs.
Below is a simple dosing conversion table to help translate mg/kg to common tablet or capsule regimens for adults of typical weights.
- 50 kg: Gallstone dosing 400–500 mg/day (eg 250 mg twice daily or 300 mg once daily + 100 mg if available).
- 70 kg: Gallstone dosing 560–700 mg/day (eg 300 mg twice daily approximates 600 mg/day).
- 90 kg: PBC dosing 1,170–1,350 mg/day (eg 500 mg twice daily + 250 mg once daily to approximate weight‑based dose).
Adjustments For Comorbidities
Children under 18 have limited established safety and efficacy; specialist oversight is required for paediatric use.
Elderly patients do not usually need routine dose reductions but require close monitoring of liver and renal function.
Avoid UDCA in decompensated liver disease or complete biliary obstruction and seek hepatology input for significant hepatic dysfunction.
Renal impairment generally does not require dose change, but clinical monitoring is advised and specialist referral considered for severe dysfunction.
Q&A — “What If I Miss A Dose?”
Take the missed dose as soon as you remember unless it is close to the next scheduled dose.
Do not double up doses to make up for a missed dose.
For repeatedly missed doses contact your prescriber to discuss adherence and whether a dosing reminder strategy is needed.
Interaction Chart
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
UDCA absorption is not strongly food‑dependent, but liver health and alcohol use are important for treatment safety.
Patients with cholestatic liver disease or PBC should avoid or limit alcohol because alcohol can worsen liver injury and affect treatment safety.
High‑fat meals change gallbladder contraction but do not cancel UDCA’s bile‑acid replacement mechanism.
Advise balanced meals and consider dietetic review for patients undergoing rapid weight loss or bariatric care.
- Limit alcohol while on UDCA, especially with pre‑existing liver disease.
- Take the medicine as prescribed; food timing can be flexible unless your prescriber advises otherwise.
- Discuss large dietary changes with your clinician if you are taking UDCA for gallstone prevention.
Common Drug Conflicts
The main interaction is with bile‑acid sequestrants such as cholestyramine or colestipol which can bind UDCA and reduce its absorption.
If a bile‑acid sequestrant is required, separate dosing from UDCA by 4–6 hours to reduce interaction.
Other drug interactions are uncommon but review other hepatotoxic medicines and polypharmacy in older patients.
If you take warfarin or other drugs with a narrow therapeutic index, monitor INR or relevant levels when starting or stopping UDCA.
| Interacting Drug | Mechanism | Counselling Points |
|---|---|---|
| Cholestyramine, Colestipol | Binding in gut reduces UDCA absorption | Separate dosing by 4–6 hours; consider alternatives where possible |
| Warfarin | Potential effect on INR when bile acids change enterohepatic circulation | Monitor INR when starting or stopping UDCA |
| Known hepatotoxic drugs | Added liver injury risk | Review therapy and monitor LFTs |
User Reports & Trends
Australian patient feedback online highlights a few recurring themes for actigall and UDCA use.
Many patients search brand terms such as Actigall 300mg and Urso 250/500 when looking for gallstone medicine without surgery.
Reported benefits include prevention of gallstones during rapid weight loss and symptom or biochemical improvement in PBC.
Common adverse reports are mild gastrointestinal effects such as diarrhoea and nausea and occasional rash.
Price sensitivity is high, with shoppers comparing Chemist Warehouse, Priceline and independent pharmacies for best value.
Rural Australians often rely on telehealth, e‑scripts and couriered pharmacy deliveries and report longer waits for specialist review.
Online forums stress the need for imaging follow‑up during gallstone therapy and frustration when off‑label use lacks monitoring.
- Top benefits: non‑surgical gallstone option, symptom improvement in PBC, relatively well tolerated.
- Top complaints: diarrhoea, nausea, rash, and cost/access issues.
- Access issues: rural delays, dependency on telehealth and courier services for medicines like Actigall 300mg.
Access & Purchase Options
National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)
UDCA is dispensed on prescription through major chains and independent pharmacies across Australia.
Chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart can often source registered generics or imported supplies and offer price comparisons.
Community pharmacists play a central role in dosing advice, prompting LFT monitoring and liaising with prescribers for PBS authority issues.
Checklist to obtain UDCA locally:
- Have a valid prescription or e‑script from your prescriber.
- Confirm PBS authority requirements if you expect a subsidy.
- Compare prices at national chains and local pharmacies for out‑of‑pocket cost.
- Ask the pharmacist about available brands, generics and likely monitoring schedules.
Online Pharmacies And Telehealth E‑Prescriptions
Telehealth e‑prescriptions are widely accepted and registered online pharmacies can dispatch to urban and rural addresses.
Confirm the online supplier is TGA‑registered and verify whether PBS subsidy transfers for online purchases.
Inspect packaging and expiry on receipt and check that storage/packaging practices match recommended conditions (store below 25°C).
In our online pharmacy, actigall is available without a prescription, with discreet delivery to Australia in 9-21 days.
| Purchase Option | Pros | Cons |
|---|---|---|
| In‑store (national chain) | Immediate counselling, PBS processing, quick pickup | Price can vary; may need authority paperwork |
| Local independent pharmacy | Personalised advice, continuity of care | May have variable stock and prices |
| Online pharmacy | Convenience, courier to remote areas, price comparison | Longer delivery times, verify TGA registration and packaging |
Mechanism & Pharmacology
Simplified Explanation
Patients often want a simple explanation of how actigall works in the body.
UDCA is a hydrophilic bile acid that replaces more toxic hydrophobic bile acids in the enterohepatic circulation.
It reduces cholesterol saturation of bile, which can promote dissolution of non‑calcified cholesterol gallstones over months.
In cholestatic liver disease UDCA improves bile flow and has cytoprotective and anti‑inflammatory effects on cholangiocytes.
Brief patient definition list:
- UDCA = gentler bile acid that replaces more toxic bile acids.
- Action = reduces cholesterol precipitation and improves bile flow.
- Outcome = possible symptom improvement and biochemical response in PBC or partial gallstone dissolution.
Clinical Terms
UDCA is classified under ATC code A05AA02 for bile acids and derivatives used in bile and liver therapy.
Pharmacokinetics include oral absorption with enterohepatic recirculation and a therapeutic effect that often takes months to appear.
Dosing is weight‑based for several indications and monitoring is required to judge response and safety.
| Aspect | Key Point |
|---|---|
| Mechanism | Replaces hydrophobic bile acids; lowers bile cholesterol saturation |
| PK Highlights | Oral absorption, enterohepatic recirculation; slow onset of clinical benefit |
| Clinical Implication | Expect months to see gallstone dissolution or biochemical improvement; monitor LFTs |
Indications & Off‑Label Uses
Approved Indications By TGA
Approved uses include dissolution of non‑calcified cholesterol gallstones and management of cholestatic liver diseases such as primary biliary cholangitis.
Standard dosing for gallstone dissolution is 8–10 mg/kg/day and for PBC is 13–15 mg/kg/day divided.
Clinicians should consult the ARTG entry for specific registered uses and PBS subsidy rules.
Off‑Label Uses In Australian Clinical Practice
Specialist off‑label uses include prevention of gallstones during rapid weight loss, for example following bariatric surgery, typically using 300 mg twice daily.
UDCA is sometimes used as adjunctive therapy for cholestatic pruritus in selected patients under specialist care.
Off‑label prescribing requires informed consent, documented monitoring including regular LFTs and imaging for gallstone therapy, and specialist oversight.
- Approved: Gallstone dissolution (non‑calcified); PBC management.
- Off‑label: Gallstone prevention during rapid weight loss; adjunctive pruritus control with specialist supervision.
Key Clinical Findings
Recent literature continues to support UDCA as a first‑line medical therapy for PBC and a non‑surgical option for selected patients with small cholesterol stones.
Randomised trials and observational data show biochemical improvement and slower disease progression in PBC with UDCA therapy.
Gallstone dissolution rates are modest and require months of therapy with imaging confirmation to assess success.
Newer agents, such as obeticholic acid, are used as adjuncts for patients with incomplete response to UDCA.
- Study Types: Randomised controlled trials, observational cohorts and national registries.
- General Outcome: Stronger evidence for PBC biochemical response than for high‑rate gallstone dissolution.
| Condition | Typical Outcome With UDCA |
|---|---|
| Primary Biliary Cholangitis | Biochemical improvement and slower progression in many patients |
| Non‑Calcified Gallstones | Modest dissolution rates over 6–24 months; imaging required to confirm |
Alternatives Matrix
PBS‑Listed Alternatives Comparison Table
| Intervention | Indication | Efficacy | Major Risks | PBS Subsidy |
|---|---|---|---|---|
| Cholecystectomy (surgery) | Symptomatic gallstones | Definitive cure for gallbladder stones | Surgical risks, anaesthesia | Typically PBS‑funded for admitted surgical care |
| Chenodiol (chenodiol) | Gallstone dissolution (where available) | Can dissolve cholesterol stones but less used | Higher hepatotoxicity risk | Varies by availability and subsidy |
| Obeticholic Acid | PBC adjunct for incomplete UDCA response | Improves biochemical markers in some UDCA non‑responders | Pruritus, lipid changes | PBS listing depends on criteria and authority |
Pros And Cons Checklist
Patients should weigh definitive cure through surgery against prolonged medical therapy with UDCA.
Consider expected monitoring such as LFTs and imaging, side effect profiles and likely costs or PBS access.
Recommend a multidisciplinary discussion with surgeon and hepatologist to individualise the best option.
Common Questions
Below are concise pharmacy‑style FAQs from typical Australian consultations.
- How long until gallstones dissolve? Months — typically 6–24 months with imaging checks.
- Can I take UDCA with other medicines? Generally yes, but separate dosing from bile‑acid sequestrants by 4–6 hours and review hepatotoxic drugs; check with your pharmacist.
- Is it safe in pregnancy? Limited data — use only if clinically indicated after specialist review.
- Will it cause weight loss? No — UDCA is not a weight‑loss drug.
- What monitoring is required? Baseline and periodic LFTs and imaging for gallstone therapy.
Also ask your pharmacist about substitution options and PBS authority requirements.
Report any severe adverse effects promptly to your prescriber or local health authority.
Price & Access Comparison Table
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required
Prices vary by brand, pack size and PBS subsidy, so pharmacies should be asked for current quotes.
| Supplier | Typical Out‑Of‑Pocket Bands | PBS Subsidy Status | Prescription Required |
|---|---|---|---|
| Chemist Warehouse | Low–Medium (varies by brand and pack size) | Depends on indication and authority | Yes — Rx required |
| Priceline | Medium (check brand availability) | Depends on indication | Yes — Rx required |
| Local Independent Pharmacy | Variable | Depends on prescriber paperwork and PBS criteria | Yes — Rx required |
| Online TGA‑Registered Supplier | Low–High (depending on import/generic) | Transferability of PBS subsidy must be confirmed | Yes — Rx required or accepted e‑script |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
Steps to obtain UDCA:
- Obtain a valid prescription (telehealth and e‑scripts are accepted).
- Confirm PBS eligibility and authority requirements with your prescriber.
- Compare prices at major chains and independents for out‑of‑pocket cost.
- For rural supply confirm courier availability and insulated packaging for hot weather.
- Keep original packaging and check expiry on receipt.
Registration & Regulation
TGA Approval
UDCA is regulated as a prescription‑only medicine and product details should be checked against the TGA’s ARTG for registered trade names and sponsors.
Importation of unregistered products for named‑patient use must follow TGA pathways with prescriber documentation.
- ARTG: Australian Register of Therapeutic Goods entry holds registration details.
- Sponsor: The entity listed on ARTG responsible for product supply.
- Prescription‑only: UDCA requires a prescription in major markets.
PBS Subsidy Details
PBS listing and subsidy depend on the clinical indication and may require authority approval for specialist conditions such as PBC.
Short‑term gallstone dissolution often does not attract PBS subsidy, so confirm the schedule before prescribing.
Counsel patients about likely out‑of‑pocket costs and ask the pharmacy to verify PBS eligibility at the time of sale.
Storage & Handling
Household Storage In Australian Climate (Heat/Humidity)
Store ursodeoxycholic acid below 25°C and protect it from moisture and heat.
Do not freeze the product and keep it in the original container to preserve stability and display expiry and lot details.
In hot Australian summers advise patients to keep the medicine in a cool, dry place away from direct sunlight and not in cars or bathrooms.
- Do: Store in a cool cupboard out of reach of children.
- Don’t: Leave bottles or blister packs in a hot car or in direct sun.
- Check: Always inspect expiry and packaging integrity on receipt.
Cold‑Chain Handling For Pharmacies
Although UDCA does not require refrigeration, it is temperature sensitive above 25°C and pharmacies should follow TGA storage guidance.
Maintain temperature logs and use insulated packaging for hot weather courier deliveries, especially to remote areas.
| Handling Step | Pharmacy SOP Note |
|---|---|
| Storage | Maintain <25°C storage area and record temperatures |
| Dispatch | Use insulated packaging in summer and document dispatch conditions |
| Documentation | Record batch and expiry on dispensing label and courier paperwork |
Guidelines For Proper Use
Australian Pharmacist Counselling Style
Pharmacists should perform safety checks including confirming indication and screening for contraindications such as complete biliary obstruction or hypersensitivity.
Review hepatic and renal status and reconcile other medicines to identify potential interactions.
Counselling should cover the INN (ursodeoxycholic acid), dose and duration, expected time to benefit (months) and common side effects such as diarrhoea, nausea and rash.
Warn patients about red‑flag symptoms that require urgent review, including allergic reactions and worsening jaundice.
Provide written dosing schedules, storage advice and reminder cards for LFTs and imaging appointments.
Patient Advice From PBS And National Health Authorities
Advise patients to verify PBS eligibility and any authority requirements with their prescriber before dispensing.
Direct patients to reputable sources for guideline updates such as the TGA ARTG and national gastroenterology or hepatology societies.
Encourage patients to report adverse events to the TGA and to keep an up‑to‑date medication list for all healthcare encounters.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 9-14 days |
| Geelong | Victoria | 9-14 days |
| Cairns | Queensland | 14-21 days |
| Townsville | Queensland | 14-21 days |